Top

Published in:

01-07-2005 | Correspondence

Early treatment with activated protein C for meningococcal septic shock: case report and literature review

Authors: Tal Hasin, David Leibowitz, David Rot, Yoram Weiss, Tova Chajek-Shaul, Ran Nir-Paz

Published in: Intensive Care Medicine | Issue 7/2005

Excerpt

Sir: Meningococcal septicemia is a devastating disease with a high risk of mortality and morbidity. These are attributed to activation of the coagulation cascade and decreased protein C (PC) activity [1]. Treatment with PC preparations in patients with Meningococcal septicemia has been advocated [2, 3], but not accepted as routine. …

Fourrier F, Leclerc F, Aidan K, Sadik A, Jourdain M, Tournoys A, Noizet O (2003) Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study. Intensive Care Med 29:1081–1087CrossRefPubMed

Alberio L, Lammle B, Esmon CT (2001) Protein C replacement in severe meningococcemia: rationale and clinical experience. Clin Infect Dis 32:1338–1346CrossRefPubMed

Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345:408–416CrossRefPubMed

Riordan FA, Marzouk O, Thomson AP, Sills JA, Hart CA (2002) Prospective validation of the Glasgow Meningococcal Septicaemia Prognostic Score. Comparison with other scoring methods. Eur J Pediatr 161:531–537CrossRefPubMed

Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B, Casey W (1997) Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 350:1590–1593CrossRefPubMed

Wcisel G, Joyce D, Gudmundsdottir A, Shasby DM (2002) Human recombinant activated protein C in meningococcal sepsis. Chest 121:292–295CrossRefPubMed

Bachli EB, Vavricka SR, Walter RB, Leschinger MI, Maggiorini M (2003) Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. Intensive Care Med 29:337PubMed

Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP (2004) Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics 113:7–17CrossRefPubMed

Rivard GE, David M, Farrell C, Schwarz HP (1995) Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 126:646–652PubMed

10.

Ettingshausen CE, Veldmann A, Beeg T, Schneider W, Jager G, Kreuz W (1999) Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 25:537–541PubMed

11.

Rintala E, Peuravuori H, Pulkki K, Voipio-Pulkki LM, Nevalainen T (2000) Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome. Intensive Care Med 26:1248–1251CrossRefPubMed

12.

White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP (2000) An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96:3719–3724PubMed

13.

Leclerc F, Cremer R, Leteurtre S, Martinot A, Fourier C (2000) Protein C concentrate and recombinant tissue plasminogen activator in meningococcal septic shock. Crit Care Med 28:1694–1697CrossRefPubMed

14.

Clarke RC, Johnston JR, Mayne EE (2000) Meningococcal septicaemia: treatment with protein C concentrate. Intensive Care Med 26:471–473CrossRefPubMed

Title: Early treatment with activated protein C for meningococcal septic shock: case report and literature review
Authors: Tal Hasin
David Leibowitz
David Rot
Yoram Weiss
Tova Chajek-Shaul
Ran Nir-Paz
Publication date: 01-07-2005
Publisher: Springer-Verlag
Published in: Intensive Care Medicine / Issue 7/2005
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-005-2653-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Early treatment with activated protein C for meningococcal septic shock: case report and literature review

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2005

Synthetic and natural surfactant differentially modulate inflammation after meconium aspiration

Inducible nitric oxide synthase inhibition improves intestinal microcirculatory oxygenation and CO2 balance during endotoxemia in pigs

Multicenter study of the multiple organ dysfunction syndrome in intensive care units: the usefulness of Sequential Organ Failure Assessment scores in decision making

A pilot study of inhaled nitric oxide in preterm infants treated with nasal continuous positive airway pressure for respiratory distress syndrome

Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients

Inhibition of inflammatory responses by FC-77, a perfluorochemical, in lipopolysaccharide-treated RAW 264.7 macrophages